pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2008-0-1-14-28pulmo-1751Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESРекомендации по диагностике и ведению больных с дефицитом α1-антитрипсина Испанского общества пульмонологии и торакальной хирургии (SEPAR)Guidelines for the diagnosis and management of α1-antitrypsin deficiencyВидальР.VidalR.

отделение пульмонологии Университетской клиники Vall d’Herbon

Барселона

БланкоИ.BlancoI.

отделение пульмонологии клиники Valle de Nalуn

Астуриас

КасасФ.CasasF.

отделение пульмонологии клиники San Cecilio

Гранада

ЖардиР.JardiR.

отделение биохимии Университетской клиники Vall d’Herbon

Барселона

МиравитлесМ.MiravitllesM.

отделение пульмонологии клинического торакального института

Барселона

Национальный регистрационный комитет дефицита α1-антитрипсинаИспанияNational Alpha-1 Antitrypsin Registry CommitteeSpain200828022008011428Copyright © Видаль Р., Бланко И., Касас Ф., Жарди Р., Миравитлес М., 20082008Видаль Р., Бланко И., Касас Ф., Жарди Р., Миравитлес М.Vidal R., Blanco I., Casas F., Jardi R., Miravitlles M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1751

.

.

ReferencesAmerican Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-antitrypsin deficiency. Am. J. Respir. Clin. Care Med. 2003; 168: 818–900.American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-antitrypsin deficiency. Am. J. Respir. Clin. Care Med. 2003; 168: 818–900.Laurell C.B., Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand. J. Clin. Invest. 1963; 15: 132–140.Laurell C.B., Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand. J. Clin. Invest. 1963; 15: 132–140.Brantly M. Alpha-1-antitrypsin: not just an antiprotease. Extending the half-life of a natural antiinflammatory molecule by conjugation with polyethylene glycol. Am. J. Respir. Cell. Mol. Biol. 2002; 27: 652–654.Brantly M. Alpha-1-antitrypsin: not just an antiprotease. Extending the half-life of a natural antiinflammatory molecule by conjugation with polyethylene glycol. Am. J. Respir. Cell. Mol. Biol. 2002; 27: 652–654.Blanco I.E., de Serres F.J., Fernández-Bustillo E. et al. Alpha1-antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Medical. Hypotheses. 2005; 64:7 59–769.Blanco I.E., de Serres F.J., Fernández-Bustillo E. et al. Alpha1-antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Medical. Hypotheses. 2005; 64:7 59–769.Sveger T. Liver disease in á1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med. 1976; 294: 1316–1321.Sveger T. Liver disease in á1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med. 1976; 294: 1316–1321.Stockley R.A. α1 -antitrypsin: more than just deficiency. Thorax 2004; 59: 363–364.Stockley R.A. α1 -antitrypsin: more than just deficiency. Thorax 2004; 59: 363–364.Miravitlles M., Vila S., Torrella M. et al. Influence of deficient alpha-1-antitrypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir. Med. 2002; 96: 186–192.Miravitlles M., Vila S., Torrella M. et al. Influence of deficient alpha-1-antitrypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir. Med. 2002; 96: 186–192.Cox D., Levison H. Emphysema of early onset associated with a complete deficiency of alpha-1-antitrypsin (null homozygotes). Am. Rev. Respir. Dis. 1988; 137: 371-375.Cox D., Levison H. Emphysema of early onset associated with a complete deficiency of alpha-1-antitrypsin (null homozygotes). Am. Rev. Respir. Dis. 1988; 137: 371-375.DeMeo D.L., Silverman E.K. a1 -antitrypsin deficiency 2: genetic aspects of á1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259–264.DeMeo D.L., Silverman E.K. a1 -antitrypsin deficiency 2: genetic aspects of á1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259–264.Blanco I., De Serres F.J., Fernández-Bustillo E. et al. Déficit de alfa-1-antitripsina en Espańa (variantes deficientes PiS y PiZ): prevalencia estimada y número de sujetos deficientes calculados para cada fenotipo. Med. Clin. (Barc.) 2004; 123: 761–765.Blanco I., De Serres F.J., Fernández-Bustillo E. et al. Déficit de alfa-1-antitripsina en Espańa (variantes deficientes PiS y PiZ): prevalencia estimada y número de sujetos deficientes calculados para cada fenotipo. Med. Clin. (Barc.) 2004; 123: 761–765.Blanco I., de Serres F.J., Fernández-Bustillo E. et al. Estimates of the prevalence of alpha-1-antitrypsin deficiency Pi*S and Pi*Z alleles and the numbers at risk in Europe countries. Eur. Respir. J. 2006 (in press).Blanco I., de Serres F.J., Fernández-Bustillo E. et al. Estimates of the prevalence of alpha-1-antitrypsin deficiency Pi*S and Pi*Z alleles and the numbers at risk in Europe countries. Eur. Respir. J. 2006 (in press).Blanco I., Fernández E., Bustillo E.F. et al. Alpha-1-antitrypsin Pi phenotypes S and Z in Europe: an analysis of the published surveys. Clin. Genet. 2001; 60: 31–41.Blanco I., Fernández E., Bustillo E.F. et al. Alpha-1-antitrypsin Pi phenotypes S and Z in Europe: an analysis of the published surveys. Clin. Genet. 2001; 60: 31–41.Silverman E.K., Pierce J.A., Province M.A. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann. Intern. Med. 1989; 111: 982–991.Silverman E.K., Pierce J.A., Province M.A. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann. Intern. Med. 1989; 111: 982–991.McElvaney N.G., Stoller J.K., Buist A.S. et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha-1-antitrypsin deficiency. Alpha-1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394–403.McElvaney N.G., Stoller J.K., Buist A.S. et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha-1-antitrypsin deficiency. Alpha-1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394–403.Eden E., Mitchell D., Mehlman B. et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am. J. Respir. Crit. Care Med. 1997; 156: 68–74.Eden E., Mitchell D., Mehlman B. et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am. J. Respir. Crit. Care Med. 1997; 156: 68–74.Wu M.C., Eriksson S. Lung function, smoking and survival in severe alpha-1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41:1157–65.Wu M.C., Eriksson S. Lung function, smoking and survival in severe alpha-1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41:1157–65.Sveger T., Piitulainen E., Arborelius M. Lung function in adolescents with alpha-1-antitrypsin deficiency. Acta Paediatr. 1994; 83: 1170–1173.Sveger T., Piitulainen E., Arborelius M. Lung function in adolescents with alpha-1-antitrypsin deficiency. Acta Paediatr. 1994; 83: 1170–1173.Piitulainen E., Tornling G., Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in nonsmoking individuals with alpha-1-antitrypsin deficiency (PiZZ). Thorax 1997; 52: 244–248.Piitulainen E., Tornling G., Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in nonsmoking individuals with alpha-1-antitrypsin deficiency (PiZZ). Thorax 1997; 52: 244–248.Piitulainen E., Tornling G., Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 1998; 53: 939–943.Piitulainen E., Tornling G., Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 1998; 53: 939–943.Janus E.D., Phillips N.T., Carrell R.W. Smoking, lung function, and alpha-1-antitrypsin deficiency. Lancet 1985; 1: 152–154.Janus E.D., Phillips N.T., Carrell R.W. Smoking, lung function, and alpha-1-antitrypsin deficiency. Lancet 1985; 1: 152–154.Seersholm N., Kok-Jensen A., Dirksen A. Decline in FEV1 among patients with severe hereditary alpha-1-antitrypsin deficiency type PiZ. Am. J. Respir. Crit. Care Med. 1995; 152: 1922–1925.Seersholm N., Kok-Jensen A., Dirksen A. Decline in FEV1 among patients with severe hereditary alpha-1-antitrypsin deficiency type PiZ. Am. J. Respir. Crit. Care Med. 1995; 152: 1922–1925.Piitulainen E., Eriksson S. Decline in FEV 1 related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (PiZZ). Eur. Respir. J. 1999; 13: 247–251.Piitulainen E., Eriksson S. Decline in FEV 1 related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (PiZZ). Eur. Respir. J. 1999; 13: 247–251.Brantly M.L., Paul L.D., Miller B.H. et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency in adults with pulmonary symptoms. Am. Rev. Respir. Dis. 1988; 138: 327–336.Brantly M.L., Paul L.D., Miller B.H. et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency in adults with pulmonary symptoms. Am. Rev. Respir. Dis. 1988; 138: 327–336.Seersholm N., Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha-1-antitrypsin deficiency. Thorax 1998; 53: 265–268.Seersholm N., Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha-1-antitrypsin deficiency. Thorax 1998; 53: 265–268.The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV 1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am. J. Respir. Crit. Care Med. 1998; 158: 49–59.The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV 1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am. J. Respir. Crit. Care Med. 1998; 158: 49–59.Buist A.S., Burrows B., Eriksson S. et al. The natural history of air-flow obstruction in PiZ emphysema. Report of a NHLBI workshop. Am. Rev. Respir. Dis. 1983; 127 (suppl.): 43–45.Buist A.S., Burrows B., Eriksson S. et al. The natural history of air-flow obstruction in PiZ emphysema. Report of a NHLBI workshop. Am. Rev. Respir. Dis. 1983; 127 (suppl.): 43–45.Seersholm N., Dirksen A., Kok-Jensen A. Airways obstruction and two-year survival in patients with severe alpha-1-antitrypsin deficiency. Eur. Respir. J. 1994; 7: 1985–1987.Seersholm N., Dirksen A., Kok-Jensen A. Airways obstruction and two-year survival in patients with severe alpha-1-antitrypsin deficiency. Eur. Respir. J. 1994; 7: 1985–1987.Novoradovsky A., Brantly M.L., Waclawiw M.A. et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha-1-antitrypsin deficiency. Am. J. Respir. Cell. Mol. Biol. 1999; 20: 441–447.Novoradovsky A., Brantly M.L., Waclawiw M.A. et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha-1-antitrypsin deficiency. Am. J. Respir. Cell. Mol. Biol. 1999; 20: 441–447.Rodrguez F., de la Roza C., Jardi R. et al. Glutathione S-transferase P1 and lung function in patients with alpha-1-antitrypsin deficiency and COPD. Chest 2005; 127: 1537–1543.Rodrguez F., de la Roza C., Jardi R. et al. Glutathione S-transferase P1 and lung function in patients with alpha-1-antitrypsin deficiency and COPD. Chest 2005; 127: 1537–1543.Dawkins P.A., Dowson L.J., Guest P.J., Stockley R.A. Predictors of mortality in alpha-1-antitrypsin deficiency. Thorax 2003; 58: 1020–1026.Dawkins P.A., Dowson L.J., Guest P.J., Stockley R.A. Predictors of mortality in alpha-1-antitrypsin deficiency. Thorax 2003; 58: 1020–1026.Seersholm N. Body mass index and mortality in patients with severe alpha-1-antitrypsin deficiency. Respir. Med. 1997; 91: 77–82.Seersholm N. Body mass index and mortality in patients with severe alpha-1-antitrypsin deficiency. Respir. Med. 1997; 91: 77–82.Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional. Arch. Bronconeumol. 1999; 35: 446–454.Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional. Arch. Bronconeumol. 1999; 35: 446–454.Blanco I, Fernández E. Alpha-1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. Respir. Med. 2001; 95: 109–114.Blanco I, Fernández E. Alpha-1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. Respir. Med. 2001; 95: 109–114.Needham M., Stockley R.A. Alfa-1-antitrypsin deficiency: Clinical manifestations and natural history. Thorax 2004; 59: 441–445.Needham M., Stockley R.A. Alfa-1-antitrypsin deficiency: Clinical manifestations and natural history. Thorax 2004; 59: 441–445.Dahl M., Tybjaerg-Hansen A., Lange P. et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha-1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann. Intern. Med. 2002; 136: 270–279.Dahl M., Tybjaerg-Hansen A., Lange P. et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha-1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann. Intern. Med. 2002; 136: 270–279.Sandford A.J., Chagani T., Weir T.D. et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am. J. Respir. Crit. Care Med. 2001; 163: 469–473.Sandford A.J., Chagani T., Weir T.D. et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am. J. Respir. Crit. Care Med. 2001; 163: 469–473.Sandford A.J., Weir T.D., Pare P.D. Genetic risk factors for chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 1380–1391.Sandford A.J., Weir T.D., Pare P.D. Genetic risk factors for chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 1380–1391.Dahl M., Hersh C.P., Ly N.P. et al. The protease inhibitor PiS allele and COPD: a meta-analysis. Eur. Respir. J. 2005; 26: 67–76.Dahl M., Hersh C.P., Ly N.P. et al. The protease inhibitor PiS allele and COPD: a meta-analysis. Eur. Respir. J. 2005; 26: 67–76.Turino G.M., Barker A.F., Brantly M.L. et al. Clinical features of individuals with PiSZ phenotype of alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 1996; 154: 1718–1725.Turino G.M., Barker A.F., Brantly M.L. et al. Clinical features of individuals with PiSZ phenotype of alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 1996; 154: 1718–1725.Álvarez-Granda L., Cabero-Pérez M.J., Bustamante-Ruiz A. et al. PiSZ phenotype in chronic obstructive pulmonary disease. Thorax 1997; 52: 659–661.Álvarez-Granda L., Cabero-Pérez M.J., Bustamante-Ruiz A. et al. PiSZ phenotype in chronic obstructive pulmonary disease. Thorax 1997; 52: 659–661.Miravitlles M., Vidal R., Torrella M. et al. Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1antitripsina. Arch. Bronconeumol. 1994; 30: 479–484.Miravitlles M., Vidal R., Torrella M. et al. Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1antitripsina. Arch. Bronconeumol. 1994; 30: 479–484.Stoller J.K. Clinical features and natural history of severe alpha-1-an-titrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997; 111 (suppl. 6): 123S–128S.Stoller J.K. Clinical features and natural history of severe alpha-1-an-titrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997; 111 (suppl. 6): 123S–128S.Miravitlles M. Enfisema por déficit de alfa-1-antripsina: żes realmente una enfermedad infrecuente? Med. Clin. (Barc.) 2004; 123: 778–779.Miravitlles M. Enfisema por déficit de alfa-1-antripsina: żes realmente una enfermedad infrecuente? Med. Clin. (Barc.) 2004; 123: 778–779.Dawson L.J., Guest P.J., Stockley R.A. The relationship of chronic sputum expectoration to physiologic, radiologic and health status characteristics in alpha-1 antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255.Dawson L.J., Guest P.J., Stockley R.A. The relationship of chronic sputum expectoration to physiologic, radiologic and health status characteristics in alpha-1 antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255.Hill A.T., Campbell E.J., Bayley D.L. et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Am. J. Respir. Crit. Care Med. 1999; 160: 1968–1975.Hill A.T., Campbell E.J., Bayley D.L. et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Am. J. Respir. Crit. Care Med. 1999; 160: 1968–1975.Alpha-1-antitrypsin deficiency: memorandum from a WHO meeting. Bulletin of the WHO. 1997; 75: 397–415.Alpha-1-antitrypsin deficiency: memorandum from a WHO meeting. Bulletin of the WHO. 1997; 75: 397–415.Miravitlles M., Vila S., Jardi R. et al. Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. Chest 2003;124: 404–406.Miravitlles M., Vila S., Jardi R. et al. Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. Chest 2003;124: 404–406.de la Roza C., Rodriguez-Frias F., Lara B. et al. Results of a case-detection programme for alpha-1-antitrypsin deficiency in COPD patients. Eur. Respir. J. 2005; 26: 616–622.de la Roza C., Rodriguez-Frias F., Lara B. et al. Results of a case-detection programme for alpha-1-antitrypsin deficiency in COPD patients. Eur. Respir. J. 2005; 26: 616–622.Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to nonindex cases. Thorax 1994; 94: 695–698.Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to nonindex cases. Thorax 1994; 94: 695–698.Vidal R., Miravitlles M., Jardi R. et al. Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona. Med. Clin. (Barc.) 1996; 107: 211–214.Vidal R., Miravitlles M., Jardi R. et al. Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona. Med. Clin. (Barc.) 1996; 107: 211–214.Jardi R., Rodriguez-Frias F., Casas F. et al. Molecular characterization of two variants of alpha-1-antitrypsin deficiency: Pi Mpalermo and Pi Plovel. Med. Clin. (Barc.) 1997; 109: 463–466.Jardi R., Rodriguez-Frias F., Casas F. et al. Molecular characterization of two variants of alpha-1-antitrypsin deficiency: Pi Mpalermo and Pi Plovel. Med. Clin. (Barc.) 1997; 109: 463–466.Jardi R., Rodriguez-Frias F., López-Talavera J.C. et al. Characterization of the new alpha1antytrypsin deficient PiM type allele, PiM Vall d’Hebron (Pro369Ser). Hum. Hered. 2000; 50: 320–321.Jardi R., Rodriguez-Frias F., López-Talavera J.C. et al. Characterization of the new alpha1antytrypsin deficient PiM type allele, PiM Vall d’Hebron (Pro369Ser). Hum. Hered. 2000; 50: 320–321.Jardi R., Rodriguez F., Miravitlles M. et al. Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256—>Val and Pro391—>His). Hum. Mutat. 1998; 12: 213.Jardi R., Rodriguez F., Miravitlles M. et al. Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256—>Val and Pro391—>His). Hum. Mutat. 1998; 12: 213.Rodriguez F., Jardi R., Costa X. et al. Rapid screening for alpha-1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am. J. Respir. Crit. Care Med. 2002; 166: 814–817.Rodriguez F., Jardi R., Costa X. et al. Rapid screening for alpha-1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am. J. Respir. Crit. Care Med. 2002; 166: 814–817.Miravitlles M., Jardi R., Rodriguez-Frias F. et al. Utilidad de la cuantificación de la banda alfa-1 del proteinogramasérico en el cribado del déficit de alfa-1-antitripsina. Arch. Bronconeumol. 1998; 34: 536–540.Miravitlles M., Jardi R., Rodriguez-Frias F. et al. Utilidad de la cuantificación de la banda alfa-1 del proteinogramasérico en el cribado del déficit de alfa-1-antitripsina. Arch. Bronconeumol. 1998; 34: 536–540.de la Roza C., Costa X., Vidal R. et al. Programa de cribado para el déficit de alfa-1-antitripsina en pacientes con EPOC mediante el uso de gota de sangre en papel secante. Arch. Bronconeumol. 2003; 39: 8–12.de la Roza C., Costa X., Vidal R. et al. Programa de cribado para el déficit de alfa-1-antitripsina en pacientes con EPOC mediante el uso de gota de sangre en papel secante. Arch. Bronconeumol. 2003; 39: 8–12.Costa X., Jardi R., Rodriguez F. et al. Easy method for screening dried blood spot specimens on filter paper for alpha-1 antitrypsin deficiency. Eur. Respir. J. 2000; 15: 1111–1115.Costa X., Jardi R., Rodriguez F. et al. Easy method for screening dried blood spot specimens on filter paper for alpha-1 antitrypsin deficiency. Eur. Respir. J. 2000; 15: 1111–1115.Vidal R., Miravitlles M., y Grupo de Estudio del Déficit de Alfa-1-anti-tripsina. Informe del Registro Espańol de Pacientes con Déficit de Alfa-1-antitripsina. Arch. Bronconeumol. 1995: 31: 299–302.Vidal R., Miravitlles M., y Grupo de Estudio del Déficit de Alfa-1-anti-tripsina. Informe del Registro Espańol de Pacientes con Déficit de Alfa-1-antitripsina. Arch. Bronconeumol. 1995: 31: 299–302.Wencker M., for the International Registry on alpha-1-antitrypsin deficiency. New formation of the International Registry on alpha-1antitrypsin deficiency as a joint database of multiple national registries. Eur. Respir. J. 1998; 12 (suppl. 28): 382.Wencker M., for the International Registry on alpha-1-antitrypsin deficiency. New formation of the International Registry on alpha-1antitrypsin deficiency as a joint database of multiple national registries. Eur. Respir. J. 1998; 12 (suppl. 28): 382.Luisetti M., Miravitlles M., Stockley R.A. Alpha-1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur. Respir. J. 2002; 20: 1050–1056.Luisetti M., Miravitlles M., Stockley R.A. Alpha-1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur. Respir. J. 2002; 20: 1050–1056.Barberŕ J.A., Peces-Barba G., Agusti A.G.N. et al. Guia clinica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch. Bronconeumol. 2001; 37: 297–316.Barberŕ J.A., Peces-Barba G., Agusti A.G.N. et al. Guia clinica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch. Bronconeumol. 2001; 37: 297–316.Miravitlles M. Tratamiento de la enfermedad pulmonar obstructive crónica. Med. Clin. (Barc.) 2005; 125: 65–74.Miravitlles M. Tratamiento de la enfermedad pulmonar obstructive crónica. Med. Clin. (Barc.) 2005; 125: 65–74.Wewers M.D., Casolaro M.A., Sellers S.E. et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 1987; 316: 1055–1062.Wewers M.D., Casolaro M.A., Sellers S.E. et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 1987; 316: 1055–1062.Dirksen A., Dijkman J.H., Madsen F. et al. A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999; 160: 1468–1472.Dirksen A., Dijkman J.H., Madsen F. et al. A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999; 160: 1468–1472.Seersholm N., Wencker M., Banik N. et al. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV 1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur. Respir. J. 1997; 10: 2260–2263.Seersholm N., Wencker M., Banik N. et al. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV 1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur. Respir. J. 1997; 10: 2260–2263.Wencker M., Fuhrmann B., Banik N. et al. Longitudinal follow-up of patients with alpha-1-protease inhibitor deficiency before and during therapy with alpha-1-protease inhibitor. Chest 2001; 119: 737–744.Wencker M., Fuhrmann B., Banik N. et al. Longitudinal follow-up of patients with alpha-1-protease inhibitor deficiency before and during therapy with alpha-1-protease inhibitor. Chest 2001; 119: 737–744.Miravitlles M., de Gracia J., Rodrigo M.J. et al. Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Chest 1999; 116: 946–952.Miravitlles M., de Gracia J., Rodrigo M.J. et al. Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Chest 1999; 116: 946–952.Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485.Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485.Stockley R.A., Bayley D.L., Unsal I., Dowson L.J. The effect of augmentation therapy on bronchial inflammation in alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2002; 165: 1494–1498.Stockley R.A., Bayley D.L., Unsal I., Dowson L.J. The effect of augmentation therapy on bronchial inflammation in alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2002; 165: 1494–1498.Hubbard R.C., Sellers S., Czerski D. et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha1-antitrypsin deficiency. J. A. M. A. 1988; 260: 1259–1264.Hubbard R.C., Sellers S., Czerski D. et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha1-antitrypsin deficiency. J. A. M. A. 1988; 260: 1259–1264.Stoller J.K., Fallat R., Schluchter M.D. et al. Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events. Chest 2003; 123: 1425–1434.Stoller J.K., Fallat R., Schluchter M.D. et al. Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events. Chest 2003; 123: 1425–1434.Stoller J.K., Rouhani F., Brantly M. et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1antitrypsin, Respitin. Chest 2002; 122: 66–74.Stoller J.K., Rouhani F., Brantly M. et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1antitrypsin, Respitin. Chest 2002; 122: 66–74.Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir. Med. 1998; 92: 1181–1187.Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir. Med. 1998; 92: 1181–1187.de la Roza C., Soy D., Lara B. et al. Can the intervals of exogenous alpha-1-antitrypsin (AAT) administration be lengthened? Am. J. Respir. Crit. Care Med. 2005; 2 (abstr. issue): A809.de la Roza C., Soy D., Lara B. et al. Can the intervals of exogenous alpha-1-antitrypsin (AAT) administration be lengthened? Am. J. Respir. Crit. Care Med. 2005; 2 (abstr. issue): A809.Vidal R., Drobnic M.E., Sala F. et al. Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave. Arch. Bronconeumol. 2006 (in press).Vidal R., Drobnic M.E., Sala F. et al. Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave. Arch. Bronconeumol. 2006 (in press).Cassina P.C., Teschler H., Konietzko N. et al. Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker’s emphysema. Eur. Respir. J. 1998; 12: 1028–1032.Cassina P.C., Teschler H., Konietzko N. et al. Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker’s emphysema. Eur. Respir. J. 1998; 12: 1028–1032.Schwaiblmair M., Vogelmeier C., Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha1-antitrypsin deficiency–three-year follow-up. Respiration. 1997; 64: 10–15.Schwaiblmair M., Vogelmeier C., Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha1-antitrypsin deficiency–three-year follow-up. Respiration. 1997; 64: 10–15.Schmidt E.W., Rasche B., Ulmer W.T. et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am. J. Med. 1988; 84 (suppl. 6A): 63–69.Schmidt E.W., Rasche B., Ulmer W.T. et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am. J. Med. 1988; 84 (suppl. 6A): 63–69.Barker A.F., Siemsen F., Pasley D. et al. Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration. Chest 1994; 105: 1406–1410.Barker A.F., Siemsen F., Pasley D. et al. Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration. Chest 1994; 105: 1406–1410.Gottlieb D.J., Luisetti M., Stone P.J. et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha-1-antitrypsin deficiency. The American-Italian AATD Study Group. Am. J. Respir. Crit. Care Med. 2000; 162: 2069–2072.Gottlieb D.J., Luisetti M., Stone P.J. et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha-1-antitrypsin deficiency. The American-Italian AATD Study Group. Am. J. Respir. Crit. Care Med. 2000; 162: 2069–2072.Stoller J.K., Aboussonan L.S. Alpha-1-antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708–712.Stoller J.K., Aboussonan L.S. Alpha-1-antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708–712.

The authors declare that there are no conflicts of interest present.